CA2792953A1 - Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation - Google Patents

Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2792953A1
CA2792953A1 CA2792953A CA2792953A CA2792953A1 CA 2792953 A1 CA2792953 A1 CA 2792953A1 CA 2792953 A CA2792953 A CA 2792953A CA 2792953 A CA2792953 A CA 2792953A CA 2792953 A1 CA2792953 A1 CA 2792953A1
Authority
CA
Canada
Prior art keywords
radiosensitizer
metal
liposomes
cancer agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2792953A
Other languages
English (en)
Inventor
Leon Sanche
Gabriel Charest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOCPRA Sciences Sante et Humaines sec
Original Assignee
SOCPRA Sciences Sante et Humaines sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOCPRA Sciences Sante et Humaines sec filed Critical SOCPRA Sciences Sante et Humaines sec
Priority to CA2792953A priority Critical patent/CA2792953A1/fr
Priority claimed from PCT/CA2010/000583 external-priority patent/WO2010121368A1/fr
Publication of CA2792953A1 publication Critical patent/CA2792953A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2792953A 2009-04-24 2010-04-26 Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation Abandoned CA2792953A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2792953A CA2792953A1 (fr) 2009-04-24 2010-04-26 Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17248209P 2009-04-24 2009-04-24
CA61/172,482 2009-04-24
CA2792953A CA2792953A1 (fr) 2009-04-24 2010-04-26 Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation
PCT/CA2010/000583 WO2010121368A1 (fr) 2009-04-24 2010-04-26 Compositions comprenant un radiosensibilisant et un agent anticancéreux et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA2792953A1 true CA2792953A1 (fr) 2010-10-28

Family

ID=47143369

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792953A Abandoned CA2792953A1 (fr) 2009-04-24 2010-04-26 Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation

Country Status (1)

Country Link
CA (1) CA2792953A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114129910A (zh) * 2021-11-18 2022-03-04 中国医学科学院肿瘤医院深圳医院 一种纳米金属放射增敏生物等效剂量的计算方法
CN114377067A (zh) * 2020-10-22 2022-04-22 中国科学院上海营养与健康研究所 葡萄籽提取物在制备靶向清除肿瘤微环境衰老细胞及抑制肿瘤的药物中的用途
CN114848653A (zh) * 2021-02-03 2022-08-05 四川大学 RORa蛋白及其激动剂在制备急性DNA损伤修复剂中的应用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114377067A (zh) * 2020-10-22 2022-04-22 中国科学院上海营养与健康研究所 葡萄籽提取物在制备靶向清除肿瘤微环境衰老细胞及抑制肿瘤的药物中的用途
CN114848653A (zh) * 2021-02-03 2022-08-05 四川大学 RORa蛋白及其激动剂在制备急性DNA损伤修复剂中的应用
CN114848653B (zh) * 2021-02-03 2023-05-30 四川大学 RORa蛋白及其激动剂在制备急性DNA损伤修复剂中的应用
CN114129910A (zh) * 2021-11-18 2022-03-04 中国医学科学院肿瘤医院深圳医院 一种纳米金属放射增敏生物等效剂量的计算方法
CN114129910B (zh) * 2021-11-18 2023-10-31 中国医学科学院肿瘤医院深圳医院 一种纳米金属放射增敏生物等效剂量的计算方法

Similar Documents

Publication Publication Date Title
US9302003B2 (en) Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof
JP4672817B2 (ja) 弱塩基性薬物を担持するイオン運搬体―中介リポゾーム
Mayhew et al. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid
CA2584279C (fr) Compositions et methodes destinees a stabiliser des preparations medicamenteuses liposomales
Bajelan et al. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance
JP5735724B2 (ja) 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
US20140037715A1 (en) Disulfiram formulation and uses thereof
US20070190182A1 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20050202074A9 (en) Method of administering liposomal encapsulated taxane
JP2006514016A (ja) リポソーム処方物
US20070190180A1 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190181A1 (en) Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
KR20150034517A (ko) 소수성 활성 성분 및 폴리펩티드의 복합체를 포함하는 리포좀, 및 그의 용도
Layek et al. Recent advances in lipid-based nanodrug delivery systems in cancer therapy
Sempkowski et al. Liposome-based approaches for delivery of mainstream chemotherapeutics: preparation methods, liposome designs, therapeutic efficacy
Di paolo Liposomal anticancer therapy: pharmacokinetic and clinical aspects
CA2792953A1 (fr) Compositions comprenant un radiosensibilisant et un agent anticancereux et leurs procedes d'utilisation
JP2006510674A (ja) 脂質：エモジン製剤に関する組成物および方法
CN101455641B (zh) 对射线敏感的抗癌药物脂质体制剂
WO2001083020A1 (fr) Composition et procede therapeutique antineoplasique a base de platine
US20160166608A1 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20220296520A1 (en) Liposome composition and preparation method thereof
US20090130194A1 (en) Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
CN107613962B (zh) 血清稳定组合物和用于光触发的材料释放的方法
ES2952680T3 (es) Eribulina para inhibir el crecimiento tumoral

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130322

FZDE Discontinued

Effective date: 20151124